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of the treatments were from published studies and the costs of treating comorbidities were from the National Health Insurance reimbursement fee schedules. All costs were updated to 2007 values using the Consumer Price Index. As they could be incurred over the lifetime of the patient, future costs were discounted at an annual rate of 5%, as recommended in Korean guidelines.
Analysis of uncertainty:
A series of one-way sensitivity analyses was conducted and a probabilistic sensitivity analysis was undertaken by fitting functional distributions for all the model parameters. The results of the probabilistic analysis were presented in a cost-effectiveness acceptability curve.
Results
For the Korean population, the number of QALYs gained, in thousands, were 18,389 for willpower, 18,502 for NRT, 18,513 for bupropion, and 18,640 for varenicline. The total costs, in thousands, were $5,576,728 for willpower, $5,798,689 for NRT, $6,351,395 for bupropion, and $6,460,784 for varenicline.
Bupropion was extendedly dominated by a combination of NRT and varenicline, which means that giving a proportion of the population NRT and the rest varenicline was less costly and more effective. When NRT was compared with willpower, the additional cost per QALY gained was $1,956. When varenicline was compared with NRT, the additional cost per QALY gained was $4,809.
The results of the probabilistic sensitivity analysis showed that at a cost-effectiveness threshold of $5,000 per QALY gained, the probability that NRT was cost-effective, compared with willpower, was 80.9%, and the probability that varenicline was cost-effective at a threshold of $10,000 per QALY, compared with NRT, was 75.2%.
